1. Home
  2. GKOS vs NYT Comparison

GKOS vs NYT Comparison

Compare GKOS & NYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$173.00

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Logo New York Times Company (The)

NYT

New York Times Company (The)

HOLD

Current Price

$63.76

Market Cap

10.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
NYT
Founded
1998
1851
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
10.1B
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
GKOS
NYT
Price
$173.00
$63.76
Analyst Decision
Strong Buy
Buy
Analyst Count
14
10
Target Price
★ $198.69
$78.56
AVG Volume (30 Days)
723.3K
★ 3.0M
Earning Date
10-28-2026
11-27-2026
Dividend Yield
N/A
★ 1.44%
EPS Growth
N/A
★ 18.08
EPS
N/A
★ 1.11
Revenue
$507,442,000.00
★ $1,783,639,000.00
Revenue This Year
$36.18
$11.16
Revenue Next Year
$23.04
$7.08
P/E Ratio
★ N/A
$57.72
Revenue Growth
★ 32.33
N/A
52 Week Low
$73.16
$54.10
52 Week High
$191.62
$87.10

Technical Indicators

Market Signals
Indicator
GKOS
NYT
Relative Strength Index (RSI) 56.54 42.06
Support Level $148.39 $62.40
Resistance Level $184.68 $73.27
Average True Range (ATR) 6.50 2.37
MACD 1.09 -0.19
Stochastic Oscillator 89.32 19.80

Price Performance

Historical Comparison
GKOS
NYT

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About NYT New York Times Company (The)

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company derives revenue from subscriptions, advertising, and other sources, where the majority of its revenue is generated through subscriptions, which consist of income from standalone and multiproduct bundle subscriptions to its digital products and subscriptions to and single-copy and bulk sales of print products.

Share on Social Networks: